CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
|<<... 4 5 6 7 8 9 10 ...>>|

Clinical Trial2020 Aug 18;9(16):e015103.

JOURNAL：J Am Heart Assoc. Article Link

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus

K Ejiri, T Miyoshi, MUSCAT‐HF Study Investigators. Keywords: B‐type natriuretic peptide; DM; HF; sodium‐glucose cotransporter 2 inhibitor

Full Text PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top